New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
10:17 EDTTEVA, LFL, EPD, RBC, JNPR, RIG, MMYT, GCIOn The Fly: Analyst Upgrade Summary
Enterprise Products (EPD) upgraded to Outperform from Neutral at Credit Suisse... Gannett (GCI) upgraded to Equal Weight from Underweight at Barclays... Juniper (JNPR) upgraded to Outperform from Market Perform at Wells Fargo... LATAM Airlines (LFL) upgraded to Strong Buy from Outperform at Raymond James... MakeMyTrip (MMYT) upgraded to Outperform from Perform at Oppenheimer... Regal-Beloit (RBC) upgraded to Outperform from Neutral at RW Baird... Teva (TEVA) upgraded to Neutral from Sell at Goldman... Transocean (RIG) upgraded to Neutral from Sell at Citigroup.
News For EPD;GCI;JNPR;LFL;MMYT;RBC;TEVA;RIG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 11, 2014
07:12 EDTTEVATeva sees FY15 Copaxone sales $3.5B-$3.7B
Sees FY15 Treanda sales $670M-$750M. Sees FY15 ProAir family sales $470M-$580M, Azilect sales $350M-$400M and Nuvigil sales $300M-$330M. Erez Vigodman, President & CEO of Teva, said, "Generics remain at the heart of our business, both as the cornerstone of the Company, but also as an area that has great impact on society. At the same time, we anticipate four specialty product approvals and five submissions in 2015 which we believe will improve treatment options for patients, and add value for all of our stakeholders." The company expects 2015 generic revenues in the United States to be $4.2B-$4.6B, $2.6B-$3.0B in Europe and $2.0B-$2.3B in its ROW markets. Results of its specialty segment are expected to be impacted by the introduction of two AB-rated generic competitors to Copaxone in the U.S. beginning in September 2015, which is a modeling assumption only, as well as by increased competition from oral products for the treatment of multiple sclerosis. In addition, the company is expecting to invest in a significant number of product launches and in its specialty pipeline. "All of these will result in lower profit and profitability, as we focus on generating growth over the next few years," Teva said.
07:08 EDTTEVATeva sees FY15 gross profit 59.5%-61.5%
Teva sees FY15 cash flow from operations $4.3B-$4.7B and free cash flow $3.5B-$3.7B.
07:07 EDTTEVATeva sees spending $1B-$1.2B on share buybacks in 2015
Subscribe for More Information
07:02 EDTTEVATeva sees FY15 EPS $5.00-$5.30, consensus $5.06
Sees FY15 revenue $19B-$19.4B, consensus $20.07B.
December 10, 2014
11:41 EDTGCIGannett sees 2014 reported revenue up 16%, consensus $5.98B
Subscribe for More Information
11:36 EDTGCIGannett sees Q4 EPS $1.00-$1.02, consensus $1.02
Gannett executives at the UBS Global Media and Communications Conference provided an update on the company's ongoing strategy and gave guidance. CFO Victoria Harker said, "Based on the trends we currently see, we estimate fourth quarter EPS to be in the range of $1.00 to $1.02."
08:31 EDTTEVATeva announces launch of first generic Celebrex capsules in the U.S.
Teva Pharmaceutical Industries (TEVA) announces the launch of the first FDA-approved generic equivalent to Celebrex Capsules in the United States. Teva is offering 50, 100, 200, and 400 mg strengths of Celecoxib Capsules. Celebrex Capsules, marketed by Pfizer (PFE) had annual sales of approximately $2.56B in the United States, according to IMS data as of October 2014.
08:16 EDTJNPRBarclays to hold a conference
Global Technology Conference is being held in San Francisco on December 9-10 with webcasted company presentations to begin on December 10 at 10:40 am; not all company presentations may be webcasted.Webcast Link
07:53 EDTGCIUBS to hold a conference
Subscribe for More Information
December 9, 2014
11:24 EDTRIGStocks with call strike movement; RIG GPRO
Transocean (RIG) May 22 call option implied volatility decreased 2% to 63, GoPro (GPRO) April 77.5 call option implied volatility decreased 5% to 58 according to IVolatility.
10:23 EDTJNPROn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:23 EDTLFLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:59 EDTLFLLATAM Airlines downgraded to Underperform from Neutral at BofA/Merrill
Subscribe for More Information
07:44 EDTTEVAAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
07:22 EDTJNPRBMO Capital to hold a conference
Subscribe for More Information
06:39 EDTJNPRJuniper initiated with a Neutral at Wedbush
Subscribe for More Information
December 8, 2014
11:31 EDTRIGStocks with call strike movement; RIG GPRO
Subscribe for More Information
11:30 EDTTEVALeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
08:21 EDTTEVAMerck says looked at all risks, including patent litgation, before Cubist deal
Subscribe for More Information
06:47 EDTTEVAArena says Teva files marketing authorization of Belviq in Israel
Arena Pharmaceuticals (ARNA) disclosed late Friday that Teva Pharmaceutical's (TEVA) local Israeli subsidiary, Abic Marketing Limited, has filed for marketing authorization of Belviq in Israel. In connection with the filing, Arena will receive a milestone payment of $250K.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use